Co-amilofruse 2.5mg/20mg tablets

País: Regne Unit

Idioma: anglès

Font: MHRA (Medicines & Healthcare Products Regulatory Agency)

ingredients actius:

Amiloride hydrochloride; Furosemide

Disponible des:

Milpharm Ltd

Codi ATC:

C03EB01

Designació comuna internacional (DCI):

Amiloride hydrochloride; Furosemide

Dosis:

2.5mg ; 20mg

formulario farmacéutico:

Oral tablet

Vía de administración:

Oral

clase:

No Controlled Drug Status

tipo de receta:

Valid as a prescribable product

Resumen del producto:

BNF: 02020400; GTIN: 8901175710119

Informació per a l'usuari

PACKAGE LEAFLET: INFORMATION FOR THE USER
CO-AMILOFRUSE 2.5/20MG TABLETS
CO-AMILOFRUSE 5/40MG TABLETS
CO-AMILOFRUSE 10/80MG TABLETS
(amiloride hydrochloride and furosemide)
READ ALL OF THIS LEAET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
•
Keep this leaet. You may need to read it again.
•
If you have any further questions, ask your doctor or pharmacist.
•
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours
•
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side effects
not listed in this leaet. See section 4.
WHAT IS IN THIS LEAET:
1.
What Co-Amilofruse Tablets are and what are they used for
2.
What you need to know before you take Co-Amilofruse Tablets
3.
How to take Co-Amilofruse Tablets
4.
Possible side effects
5.
How to store Co-Amilofruse Tablets
6.
Contents of the pack and other information
Co-Amilofruse Tablets contain the active ingredients:
•
furosemide, belonging to a group of medicines called loop diuretics
which remove excess water
but can cause a loss of potassium from the body.
•
amiloride hydrochloride belongs to a group of medicines known as
potassium sparing diuretics
which also remove excess water but prevent excessive loss of potassium
from the body.
Co-Amilofruse Tablets are prescribed for adults only for the treatment
of heart failure, kidney problems,
or uid retention due to steroids, oestrogens or cirrhosis of the
liver.
DO NOT TAKE CO-AMILOFRUSE TABLETS IF YOU:
•
have an allergy (hypersensitivity) to any of the ingredients in the
product (_see Section 6 and end of _
_Section 2_) Signs of an allergic reaction include: a rash, swallowing
or breathing problems, swelling
of your lips, face, throat or tongue.
•
have kidney failure
•
have a low blood volume or are dehydrated
•
have high blood potassium levels or any disturbance of other blood
electrolytes (salts) which

Fitxa tècnica

OBJECT 1
CO-AMILOFRUSE 20/2.5MG TABLETS
Summary of Product Characteristics Updated 26-Jul-2017 | Aurobindo
Pharma - Milpharm Ltd.
1. Name of the medicinal product
Co-Amilofruse 2.5/20mg Tablets
2. Qualitative and quantitative composition
Each tablet contains 2.5mg of Amiloride Hydrochloride (dihydrate) and
20mg of Furosemide.
For a full list of excipients, see section 6. 1.
3. Pharmaceutical form
Tablets for oral use.
Pale orange circular, flat faced beveled edge tablets, debossed with
ARD | 20 on one side and plain on the
other side.
4. Clinical particulars
4.1 Therapeutic indications
Co-Amilofruse is a potassium sparing diuretic which is indicated where
a prompt diuresis is required. It is
of particular value in conditions where potassium conservation is
important: congestive cardiac failure,
nephrosis, fluid retention due to corticosteroid or oestrogen therapy
and ascites associated with cirrhosis.
4.2 Posology and method of administration
The starting dose is usually 5/40mg, subsequent dosage being adjusted
to suit the needs of the patient.
_Adults:_
One to two tablets to be taken in the morning.
_Children:_
Not recommended for children under 18 years of age as safety and
efficacy have not been established.
_Elderly:_
The dosage should be adjusted according to diuretic response. Serum
electrolytes and urea should be
carefully monitored.
4.3 Contraindications
Patients with hypovolaemia or dehydration (with or without
accompanying hypotension). Patients with an
impaired renal function and a creatinine clearance below 30ml/min per
1.73 m
2
body surface area, anuria
or renal failure with anuria not responding to furosemide, renal
failure as a result of poisoning by
nephrotoxic or hepatotoxic agents or renal failure associated with
hepatic coma, severe hypokalaemia,
severe hyponatraemia, hyperkalaemia (serum potassium > 5.3
mmol/llitre), addison's disease,
precomatose states associated with cirrhosis, concomitant potassium
supplements or potassium sparing
diuretics, electrolyte imbalance and breast feeding women.